An analysis of data from over 3.5 million patients found comparable clinical outcomes among patients who initiated generics vs those who were treated with brand-name drugs for chronic conditions such as diabetes, hypertension, osteoporosis, depression and anxiety.
Allergan announced that the Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Applications (sBLAs) for Botox (onabotulinumtoxinA) injection for the treatment of patients aged ≥2 years with upper and lower limb spasticity.
Hazard ratio for developing CTS significantly increased for Sjögren syndrome, rheumatoid arthritis
Asthma is linked to osteopenia, osteoporosis, osteomalacia, and pathological fractures in the United States.
The Food and Drug Administration has approved Gloperba (colchicine; ROMEG Therapeutics) Oral Solution for the prophylaxis of gout flares in adults. It is the first liquid formulation of colchicine to be approved by the FDA for this indication.
According to data from on an ongoing postmarketing safety trial conducted by Pfizer, tofacitinib dosed at 10mg twice daily was associated with an increased risk of pulmonary embolism and overall mortality in patients with rheumatoid arthritis (RA).
Patients with low back pain or osteoarthritis who reported adverse drug reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) have significantly higher odds of receiving prescriptions for opioids and developing opioid use disorder compared with patients without adverse reactions to NSAIDs.
The prescribing information for Uloric (febuxostat; Takeda) is being updated to include a Boxed Warning regarding an increased risk of cardiovascular (CV) death and all-cause mortality in patients treated with the gout drug.
According to a recently conducted review of cohort and nested case-control studies, the risk of both Achilles tendon and bicep tendon rupture is increased with administration of fluoroquinolones, however, the attributable risk is actually low. The review aimed to determine the relative, absolute, and attributable risk of tendon rupture associated with fluoroquinolone, as well as…
Tanezumab, an investigational subcutaneously-administered, non-opioid treatment, may benefit patients with moderate to severe chronic low back pain (CLBP), according to top-line results from a Phase 3 study.
